Clinical Trials Sponsored by Exelixis

Total 127 results

Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Hepatocellular Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Georgia, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Philippines, ... and more
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Exelixis

Completed

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

Renal Cell Carcinoma

United States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
Exelixis

Terminated

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)

Pain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

United States, Canada, Australia, United Kingdom, Ireland
Exelixis

Terminated

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

United States
Exelixis

Completed

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

Healthy | Hepatic Impairment

United States
Exelixis

Completed

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Healthy | Renal Impairment

United States
Exelixis

Suspended

Study of XL418 in Adults With Solid Tumors

Cancer | Solid Tumors

United States
Exelixis

Recruiting

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)

Head and Neck Squamous Cell Carcinoma

United States
Exelixis

Recruiting

Study of XL309 (ISM3091) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Exelixis

Recruiting

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304)

Non-Clear Cell Renal Cell Carcinoma

United States, Spain, Korea, Republic of, Italy, Australia, France, Argentina, Brazil, Chile, Czechia, Finland, Germany, Malaysia, Netherlands, Poland, Thailand
Exelixis

Recruiting

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer

United States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
Exelixis

Recruiting

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors

United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
Exelixis

Active, not recruiting

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Exelixis

Completed

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Exelixis

Completed

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1)

Pain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

Belgium, France, Italy, Canada, United States, Germany, United Kingdom, Australia, Netherlands, Spain, Austria, Ireland, Puerto Rico, Sweden
Exelixis

Terminated

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Polycythemia Vera

United States
Exelixis

Terminated

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

Lymphoma | Cancer

United States
Exelixis

Terminated

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

Lymphoma | Cancer

United States
Exelixis

Terminated

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Cancer

United States
Exelixis

Completed

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Cancer | NSCLC | Solid Tumors

Japan
Exelixis

Withdrawn

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Cancer | Breast Cancer | Non-small-cell Lung Cancer

United States
Exelixis

Completed

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Astrocytic Tumors

United States, Canada
Exelixis

Completed

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Renal Cell Carcinoma | Papillary Thyroid Cancer | Follicular Thyroid Cancer | Huerthle Cell Thyroid Cancer

United States
Exelixis

Completed

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Gastrointestinal Neoplasms | Gastrointestinal Stromal Tumors

United States
Exelixis

Completed

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Lymphoma | Cancer | Thyroid Carcinoma

United States
Exelixis

Approved for marketing

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Medullary Thyroid Cancer

United States
Exelixis

Completed

Study of XL281 in Adults With Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Non-small-cell Lung Cancer | Papillary Thyroid Cancer

United States
Exelixis

Terminated

A Safety Study of XL019 in Adults With Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis

United States
Exelixis

Terminated

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Exelixis

Completed

Study of XL820 in Adults With Solid Tumors

Cancer

United States
Exelixis

Recruiting

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)

Colorectal Cancer

United States, Poland, Australia, Belgium, France, Hong Kong, Korea, Republic of, Spain, Hungary, Singapore, New Zealand, Germany, Thailand, Taiwan, Portugal, United Kingdom
Exelixis

Completed

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Cancer | Solid Tumors

United States, Taiwan, Belgium, Israel, United Kingdom
Exelixis

Active, not recruiting

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States
Exelixis

Active, not recruiting

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)

Medullary Thyroid Cancer

Australia, France, Israel, Spain, Russian Federation, Netherlands, Hungary, Korea, Republic of, Croatia, Italy, Canada, Poland, Romania, Sweden
Exelixis

Terminated

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Non-Hodgkin's Lymphoma (NHL) | Mantle Cell Lymphoma (MCL) | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)

United States
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)

Renal Cell Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Singapore, Spain, Taiwan, United...
Exelixis

Completed

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

Hepatocellular Carcinoma

Belgium, Hong Kong, Korea, Republic of, Canada, France, Taiwan, United States, Germany, Spain, United Kingdom, Singapore, Australia, Italy, Netherlands, Poland, Turkey, Ireland, New Zealand, Romania
Exelixis

Completed

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM)

Thyroid Cancer

France, United Kingdom, United States, Spain, Austria, Israel, Portugal, Saudi Arabia, Netherlands, Greece, Canada, Brazil, Chile, Poland, Italy, Russian Federation, Sweden, Germany, Denmark, India, Switzerland, Belgium, Korea, Republic... and more
Exelixis

Terminated

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

United States
Exelixis

Completed

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

Glioblastoma | Gliosarcoma | Giant Cell Glioblastoma

United States
Exelixis

Completed

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Exelixis

Completed

Study of XL820 Given Orally Daily to Subjects With Solid Tumors

Cancer

United States
Exelixis
Ipsen

Active, not recruiting

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Differentiated Thyroid Cancer

Hong Kong, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Taiwan, ... and more
Duke University
Exelixis

Terminated

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC)

Prostate Cancer | Prostate Cancer Adenocarcinoma | Non-Metastatic

United States
Duke University
Exelixis

Terminated

Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer (Cabo App)

Metastatic Renal Cell Carcinoma Treated With Cabozantinib

United States
Exelixis
Arcus Biosciences, Inc.

Recruiting

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

United States
University of Washington
Exelixis

Active, not recruiting

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Stage I Soft Tissue Sarcoma of the Trunk and Extremities | Stage II Soft Tissue Sarcoma of the Trunk and Extremities | Sarcoma of the Extremity | Stage IA Soft Tissue Sarcoma of the Trunk and Extremities | Stage IB Soft Tissue Sarcoma of the Trunk and Extremities

United States
University of Washington
Exelixis

Terminated

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma

United States
Bristol-Myers Squibb
Exelixis

Terminated

A Study of BMS-863233 in Patients With Hematologic Cancer

Refractory Hematologic Cancer

United States

Clinical Trials Sponsored by Exelixis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations